Valneva Stock: Declines Over 2% Despite Favorable Quarterly Dynamics

Technical Resistance and Market Indicators

Valneva's stock is currently near a resistance threshold at €5.08, a level it has not managed to surpass in recent sessions. This technical ceiling is a major point of focus: surpassing it could signal the start of a new bullish phase, while failure to do so may trigger a more pronounced consolidation movement. The RSI, an indicator measuring the speed and magnitude of price movements, stands at 71, above the generally accepted overbought threshold of 70. This suggests that the stock has appreciated rapidly and that the potential for short-term correction cannot be dismissed. Furthermore, the 20, 50, and 200-day moving averages, at €4.33, €4.11, and €3.71 respectively, all remain well below the current price, indicating a well-established underlying bullish trend across all time horizons. The negative beta of -0.24 also highlights Valneva's tendency to decouple from the overall market, a characteristic common to many biotech stocks whose catalysts are primarily linked to the progress of their clinical and regulatory portfolio.

Financial Calendar and Key Milestones

Valneva's financial calendar includes several key milestones in the coming months. The nearest is the publication of the 2025 annual results, scheduled for March 16, less than three weeks away. This event will provide an opportunity to assess the company's commercial trajectory, particularly concerning its chikungunya vaccine (Ixchiq) and other ongoing development or commercialization programs. Beyond this date, the group will present its first-quarter accounts on May 7, before holding its general meeting on June 1. The stock's performance over the past year, with a 30.25% increase, reflects changes in market perception towards the group, whose valuation remains closely tied to the progress of its vaccine strategy. However, today's decline brings the stock below the €4.80 threshold, after a weekly performance that still shows a gain of 2.72%.